We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is BioTelemetry (BEAT) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of BioTelemetry (BEAT - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of BEAT and the rest of the Medical group's stocks.
BioTelemetry is one of 817 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. BEAT is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for BEAT's full-year earnings has moved 3.07% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, BEAT has returned 66.42% so far this year. Meanwhile, stocks in the Medical group have gained about 0.35% on average. This shows that BioTelemetry is outperforming its peers so far this year.
To break things down more, BEAT belongs to the Medical Services industry, a group that includes 34 individual companies and currently sits at #52 in the Zacks Industry Rank. On average, this group has gained an average of 23.12% so far this year, meaning that BEAT is performing better in terms of year-to-date returns.
BEAT will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is BioTelemetry (BEAT) Stock Outpacing Its Medical Peers This Year?
Investors focused on the Medical space have likely heard of BioTelemetry (BEAT - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of BEAT and the rest of the Medical group's stocks.
BioTelemetry is one of 817 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. BEAT is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for BEAT's full-year earnings has moved 3.07% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, BEAT has returned 66.42% so far this year. Meanwhile, stocks in the Medical group have gained about 0.35% on average. This shows that BioTelemetry is outperforming its peers so far this year.
To break things down more, BEAT belongs to the Medical Services industry, a group that includes 34 individual companies and currently sits at #52 in the Zacks Industry Rank. On average, this group has gained an average of 23.12% so far this year, meaning that BEAT is performing better in terms of year-to-date returns.
BEAT will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.